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named after the agonists that were originally identified to selectively activate them: AMPA ( -amino-3hydroxy-5-methyl-4-isoxazole-propionic acid), NMDA (N-methyl-D-aspartate) and kainate (2-carboxy-3-carboxymethyl-4-isopropenylpyrrolidine) 1,2 . AMPA receptors are ubiquitous in the CNS and mediate the majority of fast amino acid neurotransmission. They are also critical to synaptic plasticity and the induction of long-term potentiation (LTP), the use-dependent increase in synaptic efficacy widely considered a substrate for learning and memory. Given the key role of AMPA receptors in brain physiology, a lot of early effort in terms of pharmaceutical drug development focused on the identification of AMPA receptor antagonists as a means of ameliorating the excitotoxic effects of excessive glutamate such as occurs during brain injury or ischemia. However, these compounds have failed to progress due to a variety of side effects including psychotomimetic-like effects and memory impairment. More recently, there has been a growing appreciation of the therapeutic potential of positive allosteric modulators of the AMPA receptor as a means of potentiating glutamatergic function while avoiding the attendant excitotoxic effects of direct agonists. A number of distinct classes of AMPA receptor positive allosteric modulators have been described in recent years that have been demonstrated to modulate key functional properties of AMPA receptors such as desensitization (the process of ion channel closure with agonist remaining bound to the receptor) and deactivation (the process of channel inactivation following the dissociation of agonist) which in turn modulate the amplitude and duration of synaptic responses to glutamate. These molecules have been shown to enhance synaptic transmission and LTP and increase the expression of neurotrophic factors. As such, the potential therapeutic utility of these molecules is being investigated for a variety of clinical indications such as schizophrenia, depression, Alzheimer's disease, Parkinson's disease, ADHD, and respiratory depression. Clinical data, however, is still quite limited with only 4 (CX516, Ampalex), 43 (CX717, structure not disclosed), 9 (CX691/Org 24448, farampator) and 21 (LY451395), having progressed to phase II trials. Despite concerns over potential toxicity issues with these compounds, given the link with excitotoxicity that has been associated with excessive activation of ionotropic glutamate receptors, clinical studies carried out to date have demonstrated that they have are tolerated 2 than would expected. In fact, positive allosteric modulators of the AMPA receptor appear to have relatively few adverse effects at therapeutically relevant doses, and indeed, have been shown to protect neurons against neurotoxic insults. 3 These seemingly paradoxical findings have been linked to the induction (by AMPA receptor positive modulators) of growth factors, such as BDNF which is known to possess neuroprotective properties. 4 The basic pharmacology and clinical potential of positive allosteric modulators of the AMPA receptor have been the subject of a number of extensive reviews 5, 6, 7, 8, 9, 10 which provide a broad perspective on AMPA receptors, including the mechanisms of action of various classes of modulator, the clinical, and indeed, emerging clinical evidence supporting their use in the aforementioned indications. In this article we will focus briefly on the recent developments in elucidating receptor structure and its relation to channel biophysics, followed by an overview of the various chemotypes known to modulate the channel.
Receptor structure & function
AMPA receptor subunits are encoded by four distinct genes labeled GluA1 to GluA4, which are known synonymously as GluR1 to GluR4. 11 Each of the four subunits exists as two splice variants termed 'flip' (i) or 'flop' (o) which differ by less than 10 amino acids in their extracellular domain. In particular, the Asn residue at position 754 is mutated to Ser in the 'flip' isoform. Additional complexity in the receptor stems from RNA editing, the most well characterized variant being a Gln/Arg site within the ion-channel pore of GluA2, resulting in reduced calcium permeability. An additional Arg/Gly editing site has been identified in the extracellular domains of GluA2-4.
The AMPA receptor is tetrameric, each monomer having a modular structure ( Figure 1 s. 14, 17, 18, 19 .
the intact rat GluA2 receptor has recently been determined 12, 13 and provides fascinating insights into the architecture and function of these receptors. Although the intact receptor is notionally a tetramer, this is usually comprised of heteromeric subunits from GluA1-4. The precise composition of the functional heterotetramer is variable, however, each generally contains at least one GluR2 subunit which is believed to be important in controlling Ca 2+ permeability. The structure demonstrates a symmetry mismatch, with four fold symmetry in the transmembrane regions but a two fold, dimer-ofdimer arrangement in the extracellular regions, which appears integral to the gating mechanism of all ionotropic glutamate receptors. Crystal structures of individual GluA2,A3,A4 receptor domains have also been determined 14, 15, 16 and there have been extensive studies of the GluA2 LBD and its interactions with modulators of various pharmacologie
Allosteric binding site & functional relevance
Crystal structures have shown that within a tetrameric AMPA receptor the LBD is a functional dimer, and have revealed multiple sites at which ligands can bind to influence function. The orthosteric glutamate-binding site is located within the clamshell structure of an individual LBD, and it is clear 12, 20, 
Ligand binding
Crystal structures have been reported for several of the modulators shown in Tables 1, 2 and 3 bound to the LBD of GluA2. Specifically, protein-ligand structures have been reported for benzothiadiazines such as 13 (cyclothiazide), 14 the benzamides 2 (aniracetam) 17 and 6 (CX614) 17 and the sulfonamides 20 12 and 22. 19 The different classes of modulator share distinct but overlapping binding sites, as detailed in Figure 2 . In each case, the allosteric modulator sits at the interface between two LBD clamshells, and modulates the protein-protein interaction between the two subunits, preventing the conformational changes required to move the receptor to the desensitized state.
The binding mode of 2 is shown in Figure 2A . Compound 2 makes no hydrophilic interactions with protein atoms, and forms just one hydrogen bond with a network of solvent molecules occupying the buried hydrophobic pocket. Figure 2B shows the binding mode of 13 which forms a network of hydrogen bonds with the side-chains of Ser497 and Ser754, and with mainchain atoms of Pro494 and Ser497. The norbornyl moiety is buried within the hydrophobic pocket. Figure 2C shows the binding mode of 20 (LY404187). The isopropyl sulfonamide occupies the hydrophobic pocket, and forms a single hydrogen bond with Pro494. Considered together, these three structural classes map out the surface properties and explore much of the available volume within the allosteric site. The binding site is symmetrical, with two deep, mainly hydrophobic pockets separated by a hydrophobic saddle.
Opportunities for hydrophilic interactions occur towards the extremities of the binding site, as demonstrated by the structure of 13 in Figure 2B . The hydrophobic pockets accommodate a network of solvent molecules, which can form interactions with lower potency modulators (e.g. 2) but can also be displaced by higher potency modulators such as 13 and 20. Compounds which occupy one or both of 6 these pockets appear to be advantageous, presumably as they both inhibit the conformational changes associated with desensitization, and simultaneously interact with the LBD monomers comprising the allosteric site to increase the stability of the activated state of the receptor.
Biostructural data has greatly enhanced understanding of the mechanisms underlying both the normal function and the pharmacological modulation of AMPA receptors, and is certain to remain a key factor in the identification of novel modulators of AMPA receptor function.
Chemical classes of AMPA receptor positive modulators.
Over the years, a growing body of compounds spanning a variety of chemotypes has emerged from both the chemical and patent literature, with that number burgeoning considerably in recent times.
Reporting of biological data has been complicated by the use of different cell and assay formats as well as differing measures of efficacy. The main emphasis of this article is to provide an overarching view of the established and emerging chemotypes in the area of AMPA receptor modulators as well as giving some measure of the associated SAR. The review will focus on four predominant chemical classes as well as summarizing other significant compounds of interest.
Benzamide derivatives
The benzamides were one of the first series of AMPA receptor positive modulators. This series was discovered by researchers at the University of California following chemical modification of the putative nootropic compounds 1 (piracetam) 24 and 2 25 . In early work 1 had been shown to potentiate AMPA-induced 45 Ca 2+ uptake into neuronal cultures at a concentration of 10 μM. Compound 2 has been shown to potentiate the L-glutamate evoked steady state currents at rat AMPA receptors with a low (ca >1 mM) potency with selectivity for flop over flip receptors.
Early members of the benzamide series include 3 (CX546) 26, 27, 28 and 4. 26, 27, 28, 29 These analogs, like compound 2, are weak potentiators of agonist evoked steady state currents with EC 50 values greater than 7 100 μM. Much of the electrophysiology data on these compounds has been performed using fast applications of agonists and the measurements of deactivation time constants (as opposed to long agonist applications and measuring inhibition of desensitised currents). Whole system ex vivo slice electrophysiology has also been reported extensively for benzamide series compounds, measuring so- have been claimed by researchers at Cortex. Compound 5 is claimed to increase the slice EPSC amplitude by 25% at a concentration of 300 μM. 30 Conformationally constraining 3 has given the more potent analogue 6. 31, 32 Using slice electrophysiology, a 30 μM concentration of 3 is reported to increase the slice EPSC amplitude and half-width by approximately 40% and 80% respectively, to slow the deactivation time constant by a factor of 8.4 and to enhance FW binding to rat native receptors with an EC 50 of 64 μM.
Related conformationally constrained analogues include 7 33 and 8 34 that are claimed to increase the slice EPSC amplitude by 25% at concentrations of 30 μM and 300 μM, respectively.
Structural modifications of 4 have led Cortex workers to the more potent analogue 9 35, 29 . This compound has been licenced to Organon (now Merck). Patch clamp electrophysiology indicates that 9 is approximately 10-fold more potent than 4. Compound 9 is claimed to increase the slice EPSC amplitude by 10% (3 μM).
The benz-and pyrido/thienyl-oxazepinone series of compounds have been disclosed by workers at Organon (now Merck). Compounds 10 36 and 11 37 are claimed to increase steady state currents in rat hippocampal neurones by 20 and 32%, respectively with no EC 50 values reported.
Recent work from the Servier-Cortex collaboration has resulted in the disclosure of compounds such as 12 38 which is claimed to have a two fold potentiation of the AMPA current (EC 2X ) of 0.1 µM in rat cortical cells by patch clamp electrophysiology.
The only compounds from this class to have progressed to the clinic are 4, 43 (structure not disclosed) and 9. Although 4 showed some early promise with modest effects on cognition being reported in studies with healthy human volunteers 39 40 , subsequent double-blind studies in schizophrenics failed to show any beneficial therapeutic effect, either as a monotherapy 41 or as an add-on 42 to standard antipsychotic drugs. Following up on the demonstration that 43 was able to improve cognitive performance in sleep-deprived monkeys, Cortex Pharmaceuticals reported that 43 had an alerting effect on sleep deprivation trials in healthy young men and produced some attenuation of cognitive deficits.
However, that finding failed to be replicated in a double-blind placebo-controlled trial in volunteers undergoing simulated night shift work. 43 Other more promising clinical data reported by Cortex include a phase IIa study in subjects with ADHD where 43 had a statistically significant effect on the hyperactivity subscale. Further phase IIa studies with 43 have demonstrated that it is able to prevent the onset of respiratory depression induced by an opioid, while preserving the opioid's pain-relieving effects. 44 To date there has yet to be any clinical data reported for 9. which was originally designed as a diuretic but has since been profiled extensively as a positive modulator of the AMPA receptor, (data in Table 2 ). 45 Biostructural data detailing the binding mode of 13 to the AMPA ligand binding domain is discussed above. Perhaps the most advanced member of this class is the Servier compound 14 (S-18986), which exhibited an EC 2x of 60 μM 46 in the current induced by AMPA when added to Xenopus oocytes. The Servier group demonstrated that only the (S)enantiomer was effective as an AMPA positive allosteric modulator. In spite of its relatively lower potency compared to 13, compound 14 is able to penetrate the blood-brain barrier, thus enabling in vivo investigation. 47 In vivo pharmacological studies using the object recognition test in rat showed that 14 when dosed from 0.3 to 3 mg/kg p.o. improved the retention of memory and at the 0.3 mg/kg dose counteracted the effect of age-related memory deficits. 48 Subsequent studies have shown that analogues derived from 14 have been shown to have superior levels of potency (e.g. 15 EC 2x = 8.8 μM). 45 It remains to be seen if this enhanced potency leads to improved in vivo efficacy in, for example, cognition models. 
Sulfonamide derivatives
The first examples in this class of AMPA positive modulators were reported by Lilly in 2000. 49 The progenitor alkyl-sulfonamide 16 derived from high throughput screening using a recombinant assay in which compounds were assessed for their ability to potentiate the response mediated by 100 μM Lglutamate in a stable cell line expressing homomeric GluR4 flip receptors. 28 In this assay compound 16
displayed potency (EC 50 = 19.6 μM) only five fold lower than 13, and significantly higher than that for previously reported benzamide modulators such as 4. Initial efforts by the Lilly group to further improve the potency of the modulator 16 established relatively tight SAR around the alkyl-sulfonamide region. For example, ethyl-and iso-propyl analogues showed around four-fold improved modulation compared to the parent methyl sulfonamide 16, whereas derivatives with slightly larger n-butyl and benzyl groups displayed complete loss of activity in the AMPA assay (EC 50 >100 μM). 28 Similarly, a progressive increase in size of the benzylic group showed the methyl to be the most optimal in this position. The region around the distal aromatic ring also proved important for AMPA potency, but more tolerant to structural changes. For instance, whereas deletion analogue 17 showed a significant loss of activity (EC 50 = 1980 μM), 19 replacement of the o-fluorophenyl group in 16 with structurally diverse groups such as a tert-butyl 18 and 3-thiophenyl 19 resulted in a 5-10 fold jump in the potency (EC 50 = 1.2 μM and EC 50 = 4.5 μM, respectively). Studying the effect of substitution around the distal aryl ring in combination with the most optimal iso-propyl sulfonamide functionality, Lilly scientists observed a two order of magnitude enhancement in potency for analogues containing methyl, formyl, amino or nitrile groups in the 4'position.
As one of the most potent AMPA modulators reported in the literature (GluR4 EC 50 = 0.29 μM), the nitrile analogue (±) 20 (as extensively profiled both in vitro and in vivo, and became an important and widely applied tool for further elucidation of the role of AMPA receptors in neurological disorders. 50 Equipotent at GluR2 (EC 50 = 0.15 μM), 20 was shown to be moderately selective over the other two isoforms, GluR1 (EC 50 = 5.65 μM) and GluR3 (EC 50 = 1.66 μM), 51 and essentially inactive at a range of ion channels, including other ionotropic glutamate receptors such as kainate or NMDA, and voltage gated potassium, sodium or calcium channels. 52 In addition, 20 was shown to have around 10 fold selectivity for flip (i) versus flop (o) receptors (GluR2o EC 50 = 1.44 µM). In terms of its mechanism of action, whole-cell voltage clamp using rat prefrontal cortex neurons studies revealed that 20 potentiates AMPA receptors by blocking the channel desensitization and therefore favoring an agonist-bound open state. 50 The observed high potency in the recombinant GluR4 assay translated into robust potentiation of AMPA receptors in in vitro preparations, as well as efficacy in relevant in vivo models. For example, electrophysiology studies in Purkinje neurons have shown 20 to be around 1000-fold more potent than benzamide modulators such as 4. 53 In vivo electrophysiological studies of 20 indicated a dose dependent increase in firing rate on rat hippocampal neurones with an ED 50 of 12 μg/kg. 54 Pre-clinical studies with 20 demonstrated improvements in models of working memory such as water maze and passive avoidance, 50 providing further evidence for the link between glutamatergic hypofunction and cognitive deficits in schizophrenia. It has also been reported that sub-chronic treatment of rats with 20 produced an increase in expression of BDNF, a neural growth factor for which reduced levels have been associated with depression, suggesting that this compound could also have utility as an anti-depressant.
into clinical studies. 55, 56 Very little preclinical data have been reported for this compound. It has been disclosed that compound 21 showed efficacy in preclinical cognitive models, such as the water maze and acquisition and retention in the radial arm maze, thus having a similar profile to compound 20. 8 In the clinic, 21 was found safe and well tolerated in human volunteers at doses of up to 5 mg. 57 However, in a phase II clinical study on 181 patients with Alzheimer's disease, 21 failed to show any effect on cognition. 58 The authors of the study suggested that this could potentially be due to a sub-optimal dosing regime (0.2 mg BID for 28 days followed by 1.0 mg BID thereafter up to a maximum of 8 weeks).
A recently published X-ray structure of compound 22, a closely related symmetrical analogue of 21,
co-crystallised with a soluble GluR2 construct revealed an interesting binding mode with the bissulfonamide imbedded into the GluR2 homodimeric interface. 19 The two sulfonamide moieties of 22
were shown to form an identical hydrogen-bonding pattern within the same allosteric site on the two dimerised GluR2 subunits, whereas the biaryl linker makes hydrophobic contacts with a saddle-like formation in the central part of the binding site created by Pro494 and Pro494' residues. The fact that bis-sulfonamides with greatly simplified structure such as 23a-c 59 still maintained high potency 60 ( Table 3) suggests that the isopropyl sulfonamide moiety is responsible for most of the ligand binding in this series. Flexibility in the SAR of the linker region has been further demonstrated by insertion of an amide spacer resulting in compound 24, with potency similar to the most active potentiators in the biaryl sulfonamide series (GluR4 EC 50 = 0.52 µM). 61 Further optimization efforts around this chemotype led scientists at Lilly to produce a range of constrained analogues, which generally showed at least an order of magnitude greater potency than the related open-chain ligands. 62 For instance, a 4-bromo derivative in the 2-aryl propylsulfonamide series (±) 25 showed significantly lower potency in the GluR4 assay (26% at 3 μM) than the corresponding cyclopentane derivative (±) 26 (EC 50 = 0.52 µM). With EC 50 value of 23 nM, iodo derivative (R,R) 27
was the most potent AMPA modulator among 29 examples reported in this series.
14 A series of related constrained analogues have also been disclosed by GlaxoSmithKline. Their work around this chemotype focused on insertion of heteroatoms into the molecule, possibly to optimize physicochemical properties, resulting in AMPA potentiators such as 28 (EC 50 = 1.6 µM), 29 and 30. 63, 64, 65 In their earlier efforts the GlaxoSmithKline group took an alternative constraining approach, which led to discovery of indane series, typified by 31 (EC 50 = 3 µM) and 32 (EC 50 = 10 µM). 66, 67 Limited SAR data disclosed by GlaxoSmithKline suggest generally lower AMPA potency of their constrained analogues when compared to those claimed by the Lilly group. A recent report describes how 31 had promising PK & further profiling enable the compound to reach phase I clinical trials for cognitive impairment associated with schizophrenia. 68 Most recently Pfizer have also disclosed their interest in AMPA modulators, with a patent application around a constrained sulfonamide series, exemplified by 33. 69 To date, no information on the stage in development of this series has been reported. Workers at GlaxoSmithKline have shown an interest in the tetrahydroindazole type compounds as evidenced in some recent patent applications. 70 Compounds typified by 34 have been claimed as positive allosteric modulators of the AMPA receptor, with subsequent patent applications demonstrating that modification of both the fused ring system and the amide portion are also feasible. 71 Characterisation by whole cell patch-clamp electrophysiology indicated that compounds from this class applied at a concentration of 10 nM showed a potentiation of between 14 and 79% of the current evoked by 30 μM AMPA.
Compounds such as 35 have been disclosed by GSK as clinical candidates for the treatment of cognitive defects in schizophrenia 71 . In vitro characterization by electrophysiology indicates that compounds show similar levels of efficacy to the progenitor series. Subsequent work has shown that replacement of the fused ring system substituent with 5-pyridyl or 5-cyclopropyl moieties is tolerated. 72 Most recently, a hybridization approach was applied to furnish compounds of the type 36 and 37 through combining SAR from the pyrazole series with the previously disclosed indane based derivatives. 73 A 2008 patent application from Organon (now Merck) revealed a further series of pyrazole derivatives exemplified by compound 38. 74 Variation of both the pyrazole ring and peripheral amide moiety is also presented in the same patent application. More recently, GSK have consolidated their efforts in the area of AMPA receptor modulators through the publication of a patent application concerning a series of (arylimino)dihydrothiazoles typified by compound 42. 78 When characterised by whole cell patch-clamp electrophysiology, compounds from this class applied at a concentration of 10 nM showed a potentiation of between 15 and 42% of the current evoked by 30 μM AMPA. The last few years has witnessed a significant expansion in activity in the area of positive allosteric modulators of the AMPA receptor and this review has aimed to provide an overview of the major chemotypes developed thus far. Significant advances have been made in our understanding of the molecular basis of how many of these emerging templates exert their biological effect at the receptor and this will undoubtedly facilitate the discovery of new templates as well as enabling the optimization of existing lead series. We anticipate that in the next few years the results from on-going clinical efforts in the area will come to fruition and is likely to ignite further interest in AMPA receptor modulators for the treatment of a number of debilitating neurological disorders. 
